Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.45 |
| ▸ | PTGES | O14684 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1390587 | 0.86 | POLB (0.42) | TAS1R3TAS1R1KMT2A | |
| SCHEMBL1390663 | 0.86 | ALOX5 (0.50) | MAOATAS1R3TAS1R1PTGESALOX5 | |
| SCHEMBL20559453 | 0.84 | TAS1R3 (0.56) | TAS1R3TAS1R1 | |
| SCHEMBL9826727 | 0.84 | TAS1R3 (0.56) | TAS1R3TAS1R1 | |
| Hydrochloric Acid SCHEMBL10458712 | 0.82 | TAS1R3 (0.55) | TAS1R3TAS1R1 | |
| SCHEMBL15159411 | 0.80 | ALOX5 (0.40) | MAOATAS1R3TAS1R1PTGESALOX5 | |
| SCHEMBL1391983 | 0.79 | MAOA (0.47) | MAOATAS1R3TAS1R1KMT2A | |
| SCHEMBL1390828 | 0.78 | SMN1; SMN2 (0.54) | MAOATAS1R3TAS1R1PTGESALOX5 | |
| SCHEMBL1391076 | 0.76 | CA12 (0.36) | MAOA | |
| SCHEMBL10460824 | 0.74 | CA2 (0.54) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | MAOA 3960/4885TAS1R3 4784/4885TAS1R1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.